RxDoctor Payments Data

Leonard Genovese, MD

Advanced Heart Failure and Transplant Cardiology · Brunswick, MENPI 1366702805

Payments from drug & device makers

$822in general payments, 2019–2025

Across 27 payments — averaging $30.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$175
  • United Therapeutics Corporation$110
  • Pfizer$107
  • Amgen$90
  • Kiniksa Pharmaceuticals, Ltd.$82
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$55
  • plus $203 from 7 others

What the payments were for

  • Food & beverage$822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Maineto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$59,252
Medicare patients
802
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin131$99,449
EliquisApixaban72$63,209
EntrestoSacubitril/Valsartan20$22,142
Metoprolol Succinate118$1,342
Atorvastatin Calcium79$914
Rosuvastatin Calcium22$575
Carvedilol27$481
Torsemide31$398
Losartan Potassium64$397
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$387
Furosemide49$316
Spironolactone61$211
Amlodipine Besylate25$202
Amiodarone Hcl27$190
Isosorbide Mononitrate ErIsosorbide Mononitrate15$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$54$99,449131 claims
PfizerEliquis$107$63,20972 claims
NovartisEntresto$11$22,14220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Maineon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Brunswick

Where these figures come from

Is this you, or does something look wrong? →